CliffBio
small molecule

CLEMASTINE FUMARATE

CLEMASTINE FUMARATE

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameCLEMASTINE FUMARATE
Active ingredientCLEMASTINE FUMARATE
StrengthEQ 0.5MG BASE/5ML
Dosage formSYRUP
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2000
Marketing statusDISCN

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.